|
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
|
Oct 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
|
Jun 2020
|
Leukemia
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
|
Feb 2018
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
|
Sep 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL)
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
|
Jun 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia
|
Feb 2013
|
Leukemia
|
aplastic anemia
|
|
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
|
Feb 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodyspla
|
Feb 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
